Do analysts recommend KOO or INS?

Kooth presently has a consensus price target of GBX 345, suggesting a potential upside of 85.48%. Given Kooth's stronger consensus rating and higher possible upside, equities research analysts clearly believe Kooth is more favorable than Instem. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kooth 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Instem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, KOO or INS?

Kooth has higher revenue and earnings than Instem. Instem is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kooth £63.29M 1.07 £4.00M £7.00 26.57 Instem £61.63M 0.00 £3.34M £0.14 N/A

Is KOO or INS more profitable?

Kooth has a net margin of 9.43% compared to Instem's net margin of 5.50%. Kooth's return on equity of 17.74% beat Instem's return on equity. Company Net Margins Return on Equity Return on Assets Kooth 9.43% 17.74% 10.12% Instem 5.50% 6.35% 4.62%

Do analysts rate RENX or KOO?

Kooth has a consensus target price of GBX 345, suggesting a potential upside of 85.48%. Given Kooth's stronger consensus rating and higher possible upside, analysts clearly believe Kooth is more favorable than Renalytix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Renalytix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kooth 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings & valuation, RENX or KOO?

Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Renalytix £3.30M 7.68 -£109.93M -£4.00 N/A Kooth £63.29M 1.07 £4.00M £7.00 26.57

Is RENX or KOO more profitable?

Kooth has a net margin of 9.43% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Kooth's return on equity. Company Net Margins Return on Equity Return on Assets Renalytix -506.25% 675.00% -93.54% Kooth 9.43% 17.74% 10.12%

Do analysts recommend KOO or INHC?

Kooth presently has a consensus price target of GBX 345, suggesting a potential upside of 85.48%. Given Kooth's stronger consensus rating and higher possible upside, equities analysts clearly believe Kooth is more favorable than Induction Healthcare Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kooth 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Induction Healthcare Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer FDBK or KOO?

Kooth has a consensus price target of GBX 345, suggesting a potential upside of 85.48%. Given Kooth's stronger consensus rating and higher possible upside, analysts plainly believe Kooth is more favorable than Feedback. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Feedback 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kooth 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher earnings and valuation, FDBK or KOO?

Kooth has higher revenue and earnings than Feedback. Feedback is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Feedback £849.62K 3.27 -£10.84M -£15.74 N/A Kooth £63.29M 1.07 £4.00M £7.00 26.57

Is FDBK or KOO more profitable?

Kooth has a net margin of 9.43% compared to Feedback's net margin of -845.25%. Kooth's return on equity of 17.74% beat Feedback's return on equity. Company Net Margins Return on Equity Return on Assets Feedback -845.25% -135.17% -22.99% Kooth 9.43% 17.74% 10.12%

Kooth (KOO) Competitors

GBX 186 0.00 (0.00%)

As of 10/2/2026 11:21 AM Eastern

Compare

KOO vs. INS, RENX, COG, INHC, and FDBK

Should you buy Kooth stock or one of its competitors? Kooth's main competitors and comparable companies include Instem (INS), Renalytix (RENX), Cambridge Cognition (COG), Induction Healthcare Group (INHC), and Feedback (FDBK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Kooth compare to Instem?

Kooth (LON:KOO) and Instem (LON:INS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

In the previous week, Kooth's average media sentiment score of 0.89 beat Instem's score of 0.00 indicating that Kooth is being referred to more favorably in the media.

Company	Overall Sentiment
Kooth	Positive
Instem	Neutral

21.0% of Kooth shares are owned by institutional investors. Comparatively, 65.9% of Instem shares are owned by institutional investors. 30.4% of Kooth shares are owned by company insiders. Comparatively, 30.0% of Instem shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Kooth has a beta of 1.317, meaning that its share price is 32% more volatile than the broader market. Comparatively, Instem has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Kooth has a net margin of 9.43% compared to Instem's net margin of 5.50%. Kooth's return on equity of 17.74% beat Instem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	9.43%	17.74%	10.12%
Instem	5.50%	6.35%	4.62%

Kooth has higher revenue and earnings than Instem. Instem is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£63.29M	1.07	£4.00M	£7.00	26.57
Instem	£61.63M	0.00	£3.34M	£0.14	N/A

Kooth presently has a consensus price target of GBX 345, suggesting a potential upside of 85.48%. Given Kooth's stronger consensus rating and higher possible upside, equities research analysts clearly believe Kooth is more favorable than Instem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Instem	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Kooth beats Instem on 12 of the 14 factors compared between the two stocks.

How does Kooth compare to Renalytix?

Renalytix (LON:RENX) and Kooth (LON:KOO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Kooth has a consensus target price of GBX 345, suggesting a potential upside of 85.48%. Given Kooth's stronger consensus rating and higher possible upside, analysts clearly believe Kooth is more favorable than Renalytix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Renalytix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kooth	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Renalytix has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market. Comparatively, Kooth has a beta of 1.317, indicating that its stock price is 32% more volatile than the broader market.

Kooth has a net margin of 9.43% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Kooth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Renalytix	-506.25%	675.00%	-93.54%
Kooth	9.43%	17.74%	10.12%

14.0% of Renalytix shares are held by institutional investors. Comparatively, 21.0% of Kooth shares are held by institutional investors. 5.1% of Renalytix shares are held by company insiders. Comparatively, 30.4% of Kooth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Renalytix had 4 more articles in the media than Kooth. MarketBeat recorded 4 mentions for Renalytix and 0 mentions for Kooth. Kooth's average media sentiment score of 0.89 beat Renalytix's score of 0.16 indicating that Kooth is being referred to more favorably in the news media.

Company	Overall Sentiment
Renalytix	Neutral
Kooth	Positive

Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Renalytix	£3.30M	7.68	-£109.93M	-£4.00	N/A
Kooth	£63.29M	1.07	£4.00M	£7.00	26.57

Summary

Kooth beats Renalytix on 12 of the 16 factors compared between the two stocks.

How does Kooth compare to Cambridge Cognition?

Kooth (LON:KOO) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Kooth presently has a consensus price target of GBX 345, suggesting a potential upside of 85.48%. Cambridge Cognition has a consensus price target of GBX 56, suggesting a potential upside of 103.49%. Given Cambridge Cognition's higher probable upside, analysts clearly believe Cambridge Cognition is more favorable than Kooth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kooth has higher revenue and earnings than Cambridge Cognition. Cambridge Cognition is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£63.29M	1.07	£4.00M	£7.00	26.57
Cambridge Cognition	£9.40M	1.58	-£1.58M	-£3.90	N/A

Kooth has a net margin of 9.43% compared to Cambridge Cognition's net margin of -13.86%. Kooth's return on equity of 17.74% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	9.43%	17.74%	10.12%
Cambridge Cognition	-13.86%	-54.17%	-0.30%

21.0% of Kooth shares are held by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are held by institutional investors. 30.4% of Kooth shares are held by insiders. Comparatively, 3.2% of Cambridge Cognition shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Kooth's average media sentiment score of 0.89 beat Cambridge Cognition's score of 0.00 indicating that Kooth is being referred to more favorably in the media.

Company	Overall Sentiment
Kooth	Positive
Cambridge Cognition	Neutral

Kooth has a beta of 1.317, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.809, suggesting that its share price is 19% less volatile than the broader market.

Summary

Kooth beats Cambridge Cognition on 12 of the 14 factors compared between the two stocks.

How does Kooth compare to Induction Healthcare Group?

Kooth (LON:KOO) and Induction Healthcare Group (LON:INHC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

In the previous week, Kooth's average media sentiment score of 0.89 beat Induction Healthcare Group's score of 0.00 indicating that Kooth is being referred to more favorably in the media.

Company	Overall Sentiment
Kooth	Positive
Induction Healthcare Group	Neutral

Kooth has a beta of 1.317, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Induction Healthcare Group has a beta of -0.41, meaning that its stock price is 141% less volatile than the broader market.

Kooth has higher revenue and earnings than Induction Healthcare Group. Induction Healthcare Group is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£63.29M	1.07	£4.00M	£7.00	26.57
Induction Healthcare Group	£12.57M	0.72	-£5.12M	-£5.54	N/A

Kooth presently has a consensus price target of GBX 345, suggesting a potential upside of 85.48%. Given Kooth's stronger consensus rating and higher possible upside, equities analysts clearly believe Kooth is more favorable than Induction Healthcare Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Induction Healthcare Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Kooth has a net margin of 9.43% compared to Induction Healthcare Group's net margin of -23.86%. Kooth's return on equity of 17.74% beat Induction Healthcare Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	9.43%	17.74%	10.12%
Induction Healthcare Group	-23.86%	-14.58%	-7.32%

21.0% of Kooth shares are held by institutional investors. Comparatively, 46.3% of Induction Healthcare Group shares are held by institutional investors. 30.4% of Kooth shares are held by company insiders. Comparatively, 54.6% of Induction Healthcare Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Kooth beats Induction Healthcare Group on 13 of the 15 factors compared between the two stocks.

How does Kooth compare to Feedback?

Feedback (LON:FDBK) and Kooth (LON:KOO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

In the previous week, Kooth's average media sentiment score of 0.89 beat Feedback's score of 0.00 indicating that Kooth is being referred to more favorably in the news media.

Company	Overall Sentiment
Feedback	Neutral
Kooth	Positive

Kooth has a net margin of 9.43% compared to Feedback's net margin of -845.25%. Kooth's return on equity of 17.74% beat Feedback's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Feedback	-845.25%	-135.17%	-22.99%
Kooth	9.43%	17.74%	10.12%

Kooth has higher revenue and earnings than Feedback. Feedback is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Feedback	£849.62K	3.27	-£10.84M	-£15.74	N/A
Kooth	£63.29M	1.07	£4.00M	£7.00	26.57

Feedback has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Kooth has a beta of 1.317, indicating that its stock price is 32% more volatile than the broader market.

Kooth has a consensus price target of GBX 345, suggesting a potential upside of 85.48%. Given Kooth's stronger consensus rating and higher possible upside, analysts plainly believe Kooth is more favorable than Feedback.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Feedback	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kooth	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

24.8% of Feedback shares are held by institutional investors. Comparatively, 21.0% of Kooth shares are held by institutional investors. 8.0% of Feedback shares are held by company insiders. Comparatively, 30.4% of Kooth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Kooth beats Feedback on 13 of the 15 factors compared between the two stocks.

Get Kooth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KOO vs. The Competition

Export

Metric	Kooth	Healthcare Technology Industry	Healthcare Sector	LON Exchange
Market Cap	£67.50M	£1.74B	£7.13B	£2.81B
Dividend Yield	N/A	3.95%	2.53%	6.18%
P/E Ratio	26.57	21.02	273.77	366.16
Price / Sales	1.07	85.80	614.30	89,425.30
Price / Cash	5.42	31.91	77.60	27.89
Price / Book	2.89	6.16	10.92	6.83
Net Income	£4.00M	-£26.60M	£3.50B	£5.89B
7 Day Performance	-0.53%	-1.92%	-2.07%	-0.73%
1 Month Performance	-0.11%	-1.22%	-6.21%	16.59%
1 Year Performance	28.28%	-21.49%	7.45%	23.09%

Kooth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KOO Kooth	N/A	GBX 186 flat	GBX 345 +85.5%	+27.4%	£67.50M	£63.29M	26.57	478
INS Instem	N/A	N/A	N/A	N/A	£199.62M	£61.63M	5,928.57	500
RENX Renalytix	N/A	GBX 5.87 -4.6%	N/A	-37.6%	£37.14M	£3.30M	N/A	102	News Coverage Insider Trade
COG Cambridge Cognition	1.8254 of 5 stars	GBX 28.49 +1.8%	GBX 56 +96.6%	-24.3%	£15.37M	£9.40M	N/A	74	News Coverage
INHC Induction Healthcare Group	N/A	GBX 9.75 flat	N/A	+0.0%	£9.00M	£12.57M	N/A	74

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:KOO) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kooth (KOO) Competitors